Par Pharmaceutical

Novartis to Pay $245 Million in ’Pay for Delay’ Settlement

Novartis has agreed to pay a total of $245 million to settle lawsuits filed by direct purchasers, indirect purchasers and retailers accusing it of colluding with Par Pharmaceutical to delay the launch of a generic version of its Exforge (valsartan/amlodipine) hypertension drug.

AstraZeneca Sells Gastro Treatment to Swiss Group Tillotts

U.S. Supreme Court Win Boosts Fight Against Drug Settlements

Top U.S. Court to Decide on Deals to Delay Cheaper Drugs

Par to Pay $45 Million, End US Probes Over AIDS Appetite Drug

FTC Takes "Pay for Delay" Drug Case to U.S. Supreme Court

LabCorp Unaware of Any Takeover Attempt

Small Generic Drug Firms Need Niches to Survive Looming Price War

GSK Partner Pronova Wins Fish Oil Drug Patent Fight